Company / SG&A per Share
Tarsus Pharmaceuticals, Inc. SG&A per Share History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A per Share
$11.14
FY2025
5-year range
$1.23 / $11.14
FY2021-FY2025
Trend
+60.6%
vs FY2024
Sector context
#15 of 210
Health Care
What the data says
Among 210 Health Care companies, Tarsus Pharmaceuticals, Inc. is in the bottom 7% for sg&a per share. SG&A per Share has increased for 3 consecutive years, from $1.23 in FY2022 to $11.14 in FY2025.
Based on SEC 10-K filings.
11.14 in FY2025 with a 5-year CAGR of +53.3%. Top quartile in the Health Care sector.
Increased from $4.07 to $11.14 over the past 2 years.
Health Care sector context is included.
SG&A per Share over time
Growth rates
- 3-Year CAGR
- +108.6%
- 5-Year CAGR
- +53.3%
- 10-Year CAGR
- -
Sector benchmark
Bottom 7% in Health CareTop 93% of 210This company $11.14 Sector average $40.75
▼
-72.7% below sector average
Key checks
Key Insights
- Tarsus Pharmaceuticals, Inc.'s sg&a per share has grown for 3 consecutive years.
- In FY2025, sg&a per share increased 60.6% year-over-year.
- Ranks #15 out of 210 companies in the Health Care sector.
- Lowest sg&a per share in the period was in FY2019.
Company context
Key Data Points
- Altman Z-Score 0.92 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $11.14 | +60.6% |
| FY2024 | $6.94 | +70.4% |
| FY2023 | $4.07 | +231.8% |
| FY2022 | $1.23 | -1.8% |
| FY2021 | $1.25 | -5.1% |
| FY2020 | $1.32 | +173.8% |
| FY2019 | $0.48 | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026